AN Law Firm Legal Insights Newsletter | Issue 1 | October 1, 2026

November 4, 2026
anlawfirm

The State Privacy Law Wave Heading Into 2027: What Every Company Must Have in Place Now

As 2026 draws to a close, the U.S. state privacy law landscape looks nothing like it did even a year ago. If your company collects, uses, or sells personal data — and virtually every company does — this is not a year you can afford to coast on last year’s compliance program, and 2027 will bring another round of obligations for companies that haven’t kept pace.

Texas, Oregon, and Montana have had comprehensive consumer data privacy statutes in force since 2024. Iowa, Delaware, and Tennessee followed in 2025, with Indiana, Kentucky, and Rhode Island joining on January 1, 2026. Then, in 2026, four more states enacted their own comprehensive privacy statutes, bringing the national total to 24. Louisiana and Oklahoma take effect January 1, 2027; Alabama follows on May 1, 2027; and Vermont’s law — the most protective of the four — doesn’t take effect until January 1, 2028. Companies that think they’ve finished this project should plan for three more effective dates in 2027 alone, with a fourth still to come in 2028.

Why it matters for multistate companies: Unlike GDPR, there is no single U.S. federal privacy law. With 24 states now in the mix — and Louisiana, Oklahoma, and Alabama all coming online in 2027 — a mid-size SaaS company serving consumers nationwide may be tracking two dozen overlapping sets of obligations. Companies that built compliance programs around the California Consumer Privacy Act (CCPA) alone, or even around the original 2024–2026 wave, are already behind.

The good news: a well-structured privacy program scales. Below are the core compliance requirements that appear across most of these state laws — and that every company should have in place today.

✓ Updated Privacy Notice — discloses categories of data collected, purposes of use, consumer rights, and opt-out mechanisms, tailored to each applicable state.

✓ Universal Opt-Out Signal Recognition — most states (including Colorado and California) require honoring browser-based opt-out signals such as the Global Privacy Control (GPC).

✓ Data Subject Request Process — a verified, documented intake and response workflow for access, deletion, correction, and portability requests, with compliant response timelines.

✓ Data Processing Agreements — updated vendor contracts that include processor obligations, data use restrictions, security requirements, and subprocessor provisions.

✓ Data Protection Assessments — required by several states for high-risk processing activities, including targeted advertising, sale of personal data, and certain AI-driven decisions.

✓ Sensitive Data Consent — explicit consent requirements now apply to sensitive categories (biometric data, health data, precise geolocation, etc.) under most state laws.

✓ Multistate Applicability Review — confirming which of the now 24 state laws actually apply to your business, since revenue and data-volume thresholds, sensitive-data definitions, and B2B/employee-data exemptions vary meaningfully from state to state.

The consequences of non-compliance are not theoretical. Texas’s law, for example, authorizes civil penalties up to $7,500 per violation, and the Texas AG has signaled active enforcement. Montana and Oregon have similarly equipped enforcement authorities. Alabama’s new law goes further still, authorizing penalties up to $15,000 per violation — double the $7,500 cap used by most other states. Like most of the newer state laws, enforcement runs exclusively through the state attorney general rather than a private right of action, with cure periods before enforcement ranging from 30 days (Louisiana, Oklahoma) to 45 days (Alabama) to 60 days (Vermont).

Companies that have not yet conducted a data mapping exercise, reviewed their vendor agreements, or confirmed which of the 24 (and counting) state laws apply to their business should act now — before the next wave of effective dates arrives in 2027, with Vermont’s law close behind in 2028.

The FTC’s Expanding Role in Privacy and Data Security Enforcement

While the U.S. still lacks a comprehensive federal privacy law, the Federal Trade Commission has steadily expanded its enforcement footprint — and companies that assume federal oversight is limited to the FTC’s traditional consumer protection mandate are underestimating the risk.

Under Section 5 of the FTC Act, the Commission treats inadequate data security and deceptive privacy practices as unfair or deceptive acts, and it has levied significant orders and civil penalties accordingly. Recent enforcement actions have targeted companies for: failing to implement reasonable security measures after a breach, making misleading representations about data sharing practices, retaining consumer data longer than disclosed, and using health data for advertising in ways inconsistent with disclosed purposes.

Critically, FTC orders frequently require companies to implement comprehensive information security programs, submit to third-party audits for 20 years, and obtain affirmative consumer consent before changing data practices — obligations that persist long after the original enforcement action. Companies in e-commerce, fintech, health tech, and data brokerage face the highest exposure. A robust, documented privacy and security program is no longer just a state law compliance requirement — it is the foundation of federal risk management as well.

SMS Marketing Compliance 101: The Terms Your Company Can’t Afford to Skip

Companies using SMS and MMS messaging for marketing, transactional alerts, or customer communications face a growing and actively enforced patchwork of legal obligations. The Telephone Consumer Protection Act (TCPA) remains the primary federal framework — with statutory damages of $500 to $1,500 per message and well-established class action exposure for non-compliant programs.

Beyond TCPA, The Campaign Registry (TCR) now mandates brand and campaign registration for all commercial SMS traffic over 10-Digit Long Codes (10DLC). Unregistered campaigns are filtered or blocked by major carriers — meaning messages may never reach customers even if they opted in. At the state level, Florida’s FTSA and similar statutes in Texas, Oklahoma, and Washington impose requirements beyond federal law, including stricter consent standards and per-message damages that stack rapidly.

A compliant SMS program requires, at minimum: (1) prior express written consent documented before the first marketing message; (2) standalone SMS Terms and Conditions disclosing message frequency and carrier charges; (3) a functional opt-out mechanism that processes immediately; and (4) a compliant opt-in flow that does not pre-check boxes or bury consent in general terms. If your company sends marketing texts, now is the time to audit.

AI-Powered Diagnostics and the Regulatory Frontier: What Health Tech Companies Need to Know

FDA regulates AI-enabled diagnostic and clinical decision support tools as Software as a Medical Device (SaMD) when intended to diagnose, treat, mitigate, or prevent a disease or condition. The applicable clearance pathway — 510(k), De Novo, or PMA — turns on risk classification and predicate device availability.

For AI/ML tools that learn and evolve post-market, FDA’s Predetermined Change Control Plan (PCCP) framework allows post-clearance algorithm modifications without a new 510(k) — but only if changes, validation protocols, and performance monitoring are documented and approved upfront. Companies that build products first and plan regulatory strategy second consistently face the most expensive rework.

Cybersecurity is now a mandatory submission element. FDA requires a Software Bill of Materials (SBOM), vulnerability management plan, and evidence of secure development practices in all 510(k) and PMA submissions. Separately, several states are advancing legislation governing algorithmic bias in healthcare and patient consent for AI-driven diagnoses — obligations that operate alongside, not inside, FDA’s framework. Digital health companies must track both tracks simultaneously.

Mid-Year Biotech Deal Trends: Key Structures Driving 2026 Transactions

Biotech deal activity in the first half of 2026 reflects a market recalibrating after two years of tightened capital — and the structures reflect that caution. Option-to-acquire arrangements remain the dominant Big Pharma–biotech partnership structure, allowing acquirers to purchase rights to a program after Phase 2 readouts, limiting upfront exposure while preserving access to promising science.

Collaboration and license agreements continue to dominate earlier-stage deals, with milestone-heavy structures that shift value to the back end. Development, regulatory, and commercial milestones can collectively represent 10–20x the upfront payment — making the triggering conditions of each milestone among the most negotiated provisions in any life sciences deal.

Royalty stacking — the accumulation of royalty obligations across multiple in-licensed IP rights — remains a persistent risk that buyers frequently underestimate in diligence. Freedom-to-operate analysis and chain-of-title review continue to be the top areas where deals slow down or collapse. Companies with clean, documented IP ownership and current FTO opinions close faster and at better economics.